Brief: Tenaya Therapeutics says early trial shows promise for gene therapy in rare heart condition
11/12/2025 21:05
Dec 11 (Reuters) - Tenaya Therapeutics Inc TNYA.O: TENAYA THERAPEUTICS REPORTS POSITIVE INTERIM DATA FROM COHORT 1 OF RIDGE™-1 PHASE 1B/2 CLINICAL TRIAL OF TN-401 GENE THERAPY FOR ADULTS WITH PKP2-ASSOCIATED ARVC TENAYA THERAPEUTICS INC - TN-401 WELL TOLERATED AT 3E13 VG/KG DOSE TENAYA THERAPEUTICS INC - MEANINGFUL REDUCTIONS IN ARRHYTHMIA BURDEN OBSERVED IN FIRST TWO PATIENTS WITH MORE THAN SIX MONTHS OF FOLLOW-UP TENAYA THERAPEUTICS INC: ROBUST TRANSDUCTION AND DEMONSTRATED INCREASES IN PKP2 PROTEIN LEVELS IN FIRST TWO PATIENTS AT WEEK 8 Source text: ID:nGNX8sWwFl Further company coverage: TNYA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tenaya Therapeutics
See all newsBrief: Tenaya Therapeutics Announces Interim Data From Mypeak™-1 Showing Treatment Of Mybpc3-Associated Hcm With TN-201 Gene Therapy Resulted In Consistent Signs Of Cardiac Remodeling And Reductions In Symptoms
Brief: Positive Interim Data From Cohorts 1 And 2 Of Tenaya's Ridge-1 Phase 1B/2 Clinical Trial Of TN-401
Tenaya Therapeutics Q1 net loss widens, misses analyst expectations
Brief: Tenaya Therapeutics Q1 Net Income USD -19.272 Million
Tenaya Therapeutics' Q4 net loss narrows, extends cash runway into H2 2027